aims of the present experiments were: 1) to test whether substances which modulate beta-endorphin-immunoreactive (BE-ir) release from the pituitary gland might act similarly in hypothalamic tissue; and 2) to further characterize the BE-ir forms which are released from hypothalamus. To address these questions, hypothalamic tissue was incubated in vim for 10 min periods in either normal media (basal conditions) or in media containing 55mM KCI or one of several other test substances (stimulation conditions) and release was estimated by measuring the BE-ir concentrations in the media. Depolarizing concentrations of K+ increased BE-ir release 2-3 fold over basal levels and this effect appeared to be Ca2+-dependent. Dose-dependent increases in pE-ir release were elicited by nanonolar to micromolar concentrations of either corticotropin-releasing hormone (CRH), arginine vasopressin (AVP), or 5-hydroxytryptamine (5-HT). Conversely, dopamine (1 PM) inhibited both the basal and K+-stimulated release of BE-ir from hypothalamus. Gel filtration chromatography revealed that BEI-31 and BE1_&3E~_26 were the primary BE-ir peptides released under either basal or CRH-stimulated conditions; the relative amounts of the BE-ir peptides found in the media were nearly identical to those found in the hypothalamus itself. This result indicates that the release of different BE-ir peptides into the media appears to be proportional to the relative amounts stored in tissue. In light of the critical roles of CRH and AVP in mediating stress responses in the anterior pituitary, the data showing that the same neurohormones/transmitters (i.e., CRH, AVP, 5-HT, and DA) modulate BE-ir release in both the pituitary gland and the hypothalamus suggests that endocrine and central POMC systems involved in stress responses might be regulated in a coordinate manner.
Introduction
nociception). However, it has been difficult to Beta-endorphin @E)-containing pathways in the determine the precise neurochemical and neurocentral nervous system are believed to be involved anatomical mechanisms which mediate these in a number of behavioural responses (e.g., stress, responses.
The major pro-opiomelanocortin (POMC) cell group is localized in the arcuate Date received 4 October 1989 nucleus of the hypothalamus with diverse projec- Date accepted 10 November 1989 tions to forebrain and midbrain areas including the 33 septum, amygdala, the periventricular nucleus of the thalamus, various hypothalamic nuclei, and the diencephalic/midbrain central gray region (1). In all brain regions studied to date, BE1_31, BE1_27, and BEi-are the predominant POMC products detected; except for the brainstem, only a small percentage of the BE-ir peptides in brain exist in acetylated forms (Z-5) .
While the anatomy and biochemistry of brain POMC systems are relatively well characterized, the neurochemical modulators and the mechanisms of biosynthetic regulation in these neurons are largely unknown. Initially, putative neuroregulators of pE-immunoreactive (BE-ir) release in brain were inferred from alterations in steadystate BE-ir concentrations following pharmacological manipulations. However, because of the non-specific nature of in vivo pharmacological treatments and the complexity of neural systems, researchers have used in vitro paradigms to study what modulates BE release from brain tissue. Results from in vitro studies have demonstrated that depolarizing concentrations of K+ increase /3E-ir release from hypothalamic tissue in a Ca*+-dependent manner (6) (7) (8) (9) . Corticotropin-releasing hormone (CRH) has also been shown to elicit BE-ir release and this effect is blocked by the addition of the CRH receptor antagonist, a-helical CRH+41 (10). Dopamine (DA) has been reported to increase BE-ir release from human hypothalamus (11) but to decrease release from rat hypothalamus (7). Since CRH and DA are both potent regulators of PE-ir release in the pituitary gland, one of the aims of the present studies was to examine whether other pituitary secretagogues might also alter BE-ir release from hypothalamic tissue.
or are antagonistic to (14, 15) , the opiate properties of full length 13E1_31. The precise nature of a cellular response would depend upon the relative amounts of opiate-active versus opiate-inactive BE-ir material released at a synapse. However, since evidence in both the anterior (16) and intermediate (17) lobes of the pituitary gland indicates that the PE-ir peptides stored in a tissue do not necessarily predict which peptides are released from that tissue, a second aim of these studies was to determine the PE-ir species which are secreted into the media from the hypothalamus .
Methods

Animals
Male Sprague-Dawley rats (Charles River Co., Wilmington, MA), weighing 220-250gm at the start of the experiments, were maintained in groups of 5-6 per cage, with free access to food and water, in an environmentally controlled room (12:12hr 1ight:dark cycle, lights on at 0600hr). Animals were sacrificed by decapitation between 0900 and 11OOhr and hypothalami were dissected on ice. Hypothalamic blocks, weighing 40-60mg, were defined by the optic chiasm, the mammilary bodies, the lateral hypothalamic fissures, and the top of the 3rd ventricle.
In vitro release
It has previously been shown that secretagogues release predominantly 13E1_31-size material into the media from hypothalamic tissue (8, ll), although there have also been reports that l3-LPHsize peptides represent as much as 2550% of the total PE-ir released (6, 10) . However, those chromatographic analyses did not determine whether this material was authentic PEi_31 or might be carboxy-terminal cleaved products of PEi_31, i.e., PE1_27 or 13E1_26. From a physiological standpoint, this issue could be extremely important since /3E1_27 and BEI_*~ are devoid of (12, 13), Hypothalamic blocks were sliced into 5-6 pieces and placed individually or in pairs in plastic carriers (13mm diam.) with nylon mesh on the bottom to support the tissue. Carriers were placed in tray wells (Costar) with 800 ~1 of Krebs-RingerBicarbonate (KRB) buffer (120mM NaCl, 5mM KCl, 27.5mM NaHC03, 1.2mM KH2P04, 2.6 mM CaC12, 0.7 mM MgS04) containing 0.1% BSA, 0.18% glucose, and 0.03% bacitracin. Tissue was equilibrated in this media at 37 "C with 02:C02 (95.5%) for approximately 50 min. After the equilibration period, tissues were transferred every 10 min to new wells containing either normal KRB buffer, a high concentration (55mM KCl) K+-KRB buffer, or normal KRB buffer containing a test chemical(s). The K+-KRB buffer was made isomolar with the normal KRB buffer by decreasing the NaCl concentration to 70mM. Cazf-free media was prepared by omitting CaC12 and adding 1mM EGTA. At the end of each incubation period, the buffer was collected and assayed directly by RIA to determine the amount of BE-ir that had been released into the media.
Drugs. Carbachol, dopamine HCl (DA), 5-hydroxytryptamine HCl (5HT) were obtained from Sigma (St. Louis, MO); CRH and Arg'-vasopressin (AVP) were from Bachem (Torrance, CA).
Peptide quantitation
BE-ir was measured by a radioimmunoassay using an antibody directed primarily against the midportion of BEi_ji (i.e., PEi7_27). At the concentration used in this assay (1:40000), and using "'1 N-acetyl-13El_z-I as the radiolabelled tracer, the antibody was completely crossreactive with B-LPH, p1_31, 13EI_27, BE1_z6 and their N-acetlated derivatives. The antibody did not crossreact with BE1_16, BEI..17, des-tyrosine BEi_17, BEz7_31, ACTHi-39, olMSH or yMSH or with peptides from other opioid precursors (e.g., Leu-enkephalin, Met-enkephalin, dynorphin A, dynorphin B, ol-neo-endorphin). Sensitivity of the assay under disequilibrium conditions was l-3 fmoles per tube, with an I& of approximately 13 fmoles. Tissue samples and chromatographic fractions were quantitated against a camel BE1_3i standard curve. Hypothalamic tissue was homogenized in acetone:0.2N HCl (3:1), the supernatant was dried down and aliquots were resuspended in RIA buffer (150mM Na phosphate buffer with 1% NaCl and 0.1% bovine serum albumin, pH 8.2). Media were assayed directly and were quantitated relative to a camel 13E1_3i standard curve dissolved in KRB buffer.
Gelfiltration. Different sized BE-ir forms (e.g., l3E1_3~, l3Ei_~tii_27) were determined by chromatography on a Sephadex G50-50 (1.5 x 90cm) column developed with 1% formic acid containing 0.01% BSA. When media were analyzed, 6-9 fractions of basal or CRH-stimulated fractions were pooled. Media pools or hypothalamic extracts were dried down and loaded on the column in 1% formic acid containing 0.01% BSA. Collected fractions (1.3ml) were vacuum dried, resuspended in RIA buffer, and assayed for BE-ir content. The column was pre-calibrated with dextran blue, camel PE1_31, camel PEi_27, and cobalt chloride.
Statistics
Stimulated pE-ir release was defined as the amount of BE-ir released by a test chemical minus the basal release. Basal release was calculated as the average amount of /3E-ir released in normal KRB buffer in the fraction immediately preceding and the 2 fractions following the test chemical incubation. Differences between treatment groups were statistically evaluated by t-tests or one way ANOVAs followed by Dunnett t-tests (significance level of p < 0.05).
Results
In establishing the in vitro release system, we were concerned about the possible loss of BE-ir due to enzymatic degradation and/or to adsorption (e.g., to the carrier or wells, or to the brain tissue itself). To address this issue, hypothalamic tissue was incubated in K+-KRB buffer containing 3H-BE1_31 (150000 CPM; courtesy of the late Dr C. H. Li) for either 7.5 or 30 min. Following the incubation, media was chromatographed on a Sephadex G-50-50 column and the eluted radioactivity was counted on a beta-counter. Virtually all of the radioactive /3E that was incubated in media for 7.5 min was recovered in a single peak that corresponded to the elution position of authentic B1_31 (Fig. 1) . Even after 30 min, 87% of the radioactive PE added appeared to be intact BE1_31, with the remaining radioactivity eluting at a molecular weight of 1700, the approximate eiution points of PEi-16 (a-endorphin) or BE117 (y-endorphin). No peak co-eluting with BE1_z7 was observed. These data indicate that, for the short duration incubations we used in these experiments, recovery of exogenously added BE was excellent and proteolysis of BE was minimal.
High concentrations of KC1 increased BE release from hypothalamic blocks in vitro, as 2-3 fold higher levels of PE-ir were detected when tissue was incubated in Kf-KRB buffer compared to levels found in normal KRB buffer (i.e., basal release). K+-stimulated release was reliably elicited multiple times over several hours of incubation (Fig. 2) . In studies assessing the affect of Ca2+ removal on PE-ir release, we found that basal BE-ir release was unaffected but K+-stimulated release was greatly reduced in Ca'+-free NEUROPEPTIDES media (data not shown). It should be noted that K+-induced PE-ir release was only partially inhibited when hypothalami were first incubated in normal KRB before being placed in Ca2+-free media, whereas Ca2+ removal completely blocked K+-induced release when hypothalami were first incubated in Ca2+-free media.
Different chemicals tested in these studies increased, decreased or had no effect on BE-ir levels found in the media. Dose-dependent increases in BE-ir release were induced by CRH, AVP, and 5-HT (Fig. 3) , with AVP and 5-HT being the most and least potent secretagogues, respectively. DA inhibited both basal and K+-stimulated release of BE from hypothalamus (Fig.  4) while carbachol had no effect on BE release (data not shown).
Chromatographic analyses of media collected following incubation in normal KRB or normal KRB containing 1OOnM CRF revealed that there were 2 major peaks of BE-ir, the larger peak co-eluting with the BEi_si standard and the second peak eluting with PEi_&Ei_26 (which could not be separated on this column; Fig. 5a ). The relative amounts of PEi-31 and BEi_&Ei_26 found in media under basal and stimulated conditions did not differ significantly (1.1: 1 and 1.3:1, respectively). Furthermore, the peptide forms of BE found in media were nearly identical to those found in hypothalamic tissue (PE1_31:PE1_2,/PE1_26 ratio = 1.3:1; Fig. 5b ). Fig. 2 A typical experiment demonstrating basal and K+-stimulated BE-ir release from hypothalamus. Hypothalamic tissue was incubated for 10 min periods in either normal KRB buffer or in 55mM K+-KRB buffer (indicated by the arrows). Media was frozen immediately following incubation and later assayed directly for BE-ir. The data are expressed as fmoles of BE-ir detected per 10 min incubation period. Fig. 3 Dose-dependent release of BE-ir from hypothalamus by CRH, AVP and 5-HT. Hypothalamic tissue was incubated for 10 min periods in either normal KRB buffer or in normal KRB containing different concentrations of CRH, AVP or 5-HT. BE-ir in the media was measured by RIA and is expressed as fmoles BE-ir per 10 min incubation period. Data represents the means + S.E.M. of 2-8 different incubation periods. * p < 0.01, ** p < 0.001 compared to control (no drug) group. 
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Discussion
The two main findings in these studies were: 1) in vitro release of PE from hypothalamus was stimulated in a dose-dependent manner by CRH, AVP, and 5-I-U and was inhibited by DA; and 2) the relative amounts of PE1_31 and PE1_~#E1_26 released into the incubation media, under either basal or stimulated conditions, mirrored PE-ir forms found in hypothalamic tissue. These results characterizing PE-ir release from the hypothalamus will be discussed in relation to the regulation of PE-ir release from the pituitary gland.
In these studies, we demonstrated that 55mM K+, as well as a number of putative neurotransmitters, increased the secretion of BE-ir into the incubation buffer. That this increase reflects stimulation-induced release of PE-ir from hypothalamic tissue is supported by the fact that release appears to be Ca'+-dependent, i.e., depolarization-induced Ca2+ influx appears necessary for release. Furthermore, the similarity between the relative amounts of PE1_31 and PE&PE~_z~ found in hypothalamus and media suggests that the PE-ir peptides found in the media are most likely derived by release from intracellular pools. While we cannot exclude the possibility that the QE-ir forms detected in the media are proteolytically derived from larger BE-ir peptides released from tissue, our data showing minimal degradation of exogenously added 3H-PE (see Fig.  1 ) and the fact that larger BE-ir peptides are not stored in the hypothalamus argue against this possibility. Rather, we believe these data indicate that the PE-ir peptides released from hypothalamic POMC neurons in vitro reflect the proportional
In contrast to in the hypothalais evidence that proportional of stored PE-ir species in either or intermediate lobes of the pituitary as much P-lipoprotein (p-LPH) PE1_sl is stored anterior lobe corticotrophs, is released by an acute stressor in vivo or by CRH in vitro (16). One explanation for the discrepancy between the peptides that a cell stores and those it releases is that the extent of POMC processing may not be the same in all vesicles within an individual cell; vesicles containing more processed BE-ir species may accumulate closer to the outer membrane, Media   Fig. 5 Different sized BE-ir peptides found in a) media and b) hypothalamus. Hypothalamic tissue was incubated in normal KRB buffer or normal KRB containing W6M CRH. Media from basal and CRH-stimulated fractions were pooled and hypothalamic tissue was extracted in acetone:O. 1 N HCI (3: 1). a) Media pools or b) hypothalamic extracts were developed on a Sephadex G-50-50 column with 1.0% formic acid containing 0.01% BSA and f3E-ir was measured in collected fractions by RIA. Data are expressed as a) fmoles orb) pmoles of BE-ir per fraction. The elution positions of synthetic camel pE1_31 and PEI_z~ are indicated. making these pools more releasable. A second possibility is that subpopulations of corticotrophs in the pituitary, storing different mixtures of POMC-processed peptides, have different sensitivities to secretagogues such as CRH or AVP. Since the various PE-ir peptide products produce extremely different behavioural and physiological effects (e.g., N-acetylation or carboxy-terminal cleavage of PEi_31 result in products which are much weaker opioid agonists than the original peptide (12,13,15)), the possibility that cells could selectively release a particular peptide product under different conditions is extremely exciting.
However, under the conditions tested in the present experiments, hypothalamic POMC cells did not exhibit this property. It would be interesting to determine whether proportional PE-ir release from hypothalamic tissue would still occur if the relative amounts of l3E1-3~ and PE1_z7 stored in cells were experimentally altered.
An important question to address is whether the stimulatory effects of CRH, AVP and 5-HT on PER-ir release are mediated directly at POMC cells or indirectly by modulating transmitter release from other neurons which synapse upon POMC cells. Since binding sites for CRH (20), AVP (21), and 5-HT (22) have been demonstrated in the hypothalamus, it is possible that POMC cells possess each type of these receptors and can thus be directly stimulated by these secretagogues. However, until these different receptor types are localized to POMC-containing cells in particular, it will be difficult to ascertain whether some or all of these transmitters are acting directly or whether one of these substances might act as a final common transmitter in modulating PE release. It is interesting that in the hypothalamus, AVP appears to be approximately 10 fold more potent than CRH in stimulating PE-ir release, whereas the converse is true in the anterior pituitary either in vivo (28) or in vitro (29) . One reason why CRH appears to be a less potent PE secretagogue than AVP in the hypothalamus might be because it is acting via other neurons to stimulate PE release while AVP stimulates secretion directly from POMC neurons. A second explanation for the reversed sensitivities to CRH and AVP may be related to the relative distribution of the receptors for these peptides in brain and pituitary POMC cells. For example, if the majority of corticotrophs possess CRH receptors and the remainder of cells contain AVP receptors, then CRH could appear to be a more potent l3E secretagogue than AVP; conversely, the majority of hypothalamic POMC neurons may contain AVP receptors, making this tissue more sensitive to AVP relative to CRH. Detailed neuroanatomical mapping of the hypothalamus, in conjuction with immunohistochemistry and receptor autoradiography, will aid in resolving which, if any, of these explanations are correct. The fact that there is a rich supply of CRH, AVP, and 5-HT nerve terminals (30, 31) and binding sites (20) (21) (22) in the hypothalamus supports the possiblity that CRH, AVP, and 5-HT have physiological effects similar to the pharmacological ones observed here.
Addition of DA to the incubation media inhibited both basal and K+-stimulated release of PE-ir from hypothalamus. The mechanism by which DA inhibits either basal or stimulated PE-ir release from the hypothalamus is presently not known. In fact, it is unclear what the PE-ir found in the media under basal conditions actually represents. While it may reflect the basal rate of release from spontaneously discharging neurons, it may also represent, at least in part, peptide that has been discharged from dying cells. However, the fact that DA significantly inhibited basal release suggests that tonic l3E release may be an active mechanism which can be modulated by inhibitory neurotransmitters.
The most intriguing aspect of the present results is that each of the substances which modulate PE-ir release from hypothalamic tissue (i.e., CRH, AVP, 5-HT, DA) have previously been shown to produce similar effects on ACTH and PE release in the anterior pituitary gland (23) (24) (25) (26) (27) . Given the functional importance of CRH and AVP in mediating stress responses in the pituitary, it is reasonable to speculate that these agents might also play a role in stress responses in the central nervous system. There is evidence to indicate that brain opioid systems, in particular POMC systems, are involved in stress responses. For example, there is a significant decrease in PE-ir in the hypothalamus after footschock stress (32) (33) . Following repeated exposure to this stressor, midbrain concentrations of PE-ir peptides and hypo-thalamic POMC mRNA levels increase, suggesting that POMC biosynthesis has accelerated in response to the increased drive upon this system (Akil et al., in preparation) . The stressinduced changes in POMC peptides and mRNA observed in the brain follow similar patterns to those seen in the anterior pituitary gland (34) . Although the roles of CRH and/or AVP in producing stress-induced changes in POMC systems in the brain have not been established (as they have in the anterior pituitary), the present data suggest the possibility that the same transmitters (i.e., CRH, AVP and perhaps 5-HT and DA) may be involved in regulating the two higher levels of the hypothalamo-pituitary-adrenal (HPA) axis. Regulation of PE-ir release in both the pituitary and hypothalamus by common neurohormones/ transmitters may represent a mechanism by which organisms coordinate central and endocrine responses to stress.
